10:11 AM EST - HLS Therapeutics Inc. : Announces its financial results for the 12-month periods ended December 31, 2022. All amounts are in United States dollars unless otherwise stated. 2022 revenue of $61.5 million, Adjusted EBITDA of $23.8 million and cash-flow from operations of $16.9 million. 2022 net loss was ($23.6) million, compared to net loss of ($13.1) million in 2021. HLS Therapeutics Inc.
shares T.HLS are trading down $1.56 at $6.99.
